申请人:Takeda Chemical Industries, Ltd.
公开号:US05654309A1
公开(公告)日:1997-08-05
Pyridopyrimidine derivatives of the formula (A), wherein n denotes an integer of 0 to 3, Q stands for --(CH.sub.2).sub.m --, --O--, --S(O).sub.P -- or --N--, and R.sup.1 to R.sup.5 stand for substituents, where R.sup.3 is an optionally substituted phenyl, naphthyl, pyridyl, quinolyl, quinolonyl, or thienyl group; or its salt are described. Preparation and use of the derivatives for an antagonistic agent for an endothelin receptor are shown. An endothelin receptor antagonist including the derivative is effective as a therapeutic composition of acute renal insufficiency, myocardial infarction, hypertension, cerebral infarction, angina pectoris, arteriosclerosis, hepatopathy, pulmonary hypertension, bronchial asthma, organohypofunction occurring during operation of transplantation of organs. ##STR1##
该公式中的吡啶吡嗪衍生物(A),其中n表示0到3的整数,Q代表--(CH.sub.2).sub.m --,--O--,--S(O).sub.P --或--N--,R.sup.1到R.sup.5代表取代基,其中R.sup.3是可选择取代的苯基、萘基、吡啶基、喹啉基、喹啉基或噻吩基;或其盐。描述了该衍生物的制备和用途,作为内皮素受体拮抗剂。包括该衍生物的内皮素受体拮抗剂作为急性肾功能不全、心肌梗死、高血压、脑梗死、心绞痛、动脉硬化、肝病、肺动脉高压、支气管哮喘、器官移植手术中发生的器官功能减退的治疗组合物。